Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTBEAM-U01 Substudy 01C of patritumab deruxtecan in pediatric recurrent or refractory solid tumors
MOH_2025-05-18_014101Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patritumab deruxtecan in hepatoblastoma and rhabdomyosarcoma (RMS), sponsored by Merck & Co. Started May 2025; status: recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
hepatoblastomarhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on MOH_2025-05-18_014101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-05-18_014101.